TABLE 1

Baseline characteristics of women who returned for at least one follow-up visit after randomization to placebo or troglitazone

|  |  |  |  |
| --- | --- | --- | --- |
|  | Placebo group | Troglitazone group | P |
| n | 122 | 114 |  |
| Clinical characteristics |  |  |  |
| Age (years) | 34.3±6.5 | 34.3±6.5 | 0.52 |
| BMI (kg/m2) | 30.3±5.3 | 30.6±6.1 | 0.63 |
| Waist-to-hip circumference ratio | 0.86±0.05 | 0.85±0.06 | 0.19 |
| Using hormonal contraceptives\* | 48% | 43% | 0.41 |
| OGTT† |  |  |  |
| Fasting glucose (mg/dl) | 98.1±9.1 | 98.7±10.2 | 0.64 |
| 2-h glucose 154.0 | 154.0±24.0 | 154.4±27.0 | 0.97 |
| Total glucose area (mg/dl \_ min \_ 10\_3) | 18.7±2.0 | 18.9±2.0 | 0.25 |
| Impaired glucose tolerance§ | 72% | 69% | 0.66 |
| Fasting insulin (U/ml) | 16.0±7.5 | 17.0±10.8 | 0.82 |
| Total insulin area (U/ml \_ min)‡ | 10,209±5536 | 9,902±6543 | 0.5 |
| IVGTT\_ |  |  |  |
| Fasting glucose (mg/dl) | 94.3±10.4 | 94.8±10.2 | 0.71 |
| *K*g (min\_1 \_ 100)¶ | 1.48±0.40 | 1.42±0.39 | 0.23 |
| Fasting insulin (U/ml) | 18.7±9.7 | 16.6±9.5 | 0.05 |
| *S*i (min\_1 per U/ml \_ 10\_4)# | 2.28±1.75 | 2.64±1.70 | 0.05 |
| AIRg (U/ml \_ min)\*\* | 569±527 | 454±360 | 0.18 |
| Total insulin area (units/ml \_ min)‡ | 10,686±5686 | 9,273±5434 | 0.3 |
| DI (*S*I \_ AIRg)†† | 983±697 | 976±717 | 0.99 |